Navigation Links
Digirad Names Two Veteran Healthcare Executives to Board
Date:5/20/2009

Steven C. Mendell and Lloyd H. Malchow Join Digirad Board of Directors

POWAY, Calif., May 20 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD) today announced that it has named veteran healthcare executives Steven C. Mendell and Lloyd H. Malchow to its Board of Directors, effective immediately. The addition of Messrs. Mendell and Malchow expands the board to a total of seven members.

"Steve and Lloyd both have the experience and business acumen that will make them immediate contributors to our board and to the strategic advancement of Digirad," said R. King Nelson, Digirad's Chairman of the Board of Directors. "Our stated goal is to rapidly return Digirad to a platform of consistent profitability and positive cash flow that will allow us to move to the next stage of growth and strategic development. Steve and Lloyd have the kinds of broad-based expertise in healthcare, operations and business development that will help guide us in this process. We welcome them to our board and look forward to working closely with them."

Mr. Mendell, 67, has more than 30 years of experience in the management of healthcare-related businesses. From 1999 to 2007 he worked for San Diego-based LMA North America, Inc., and was most recently its President and Chief Executive Officer. LMA, a publicly traded company in Singapore, is a global leader in the manufacture and distribution of medical devices related to air flow and anesthesia needed during surgery and life-saving interventions. Prior to LMA, Mr. Mendell was President and Chief Executive Officer of San Diego-based Prizm Pharmaceuticals.

Mr. Mendell was a member of the Board of Directors of San Diego-based Gensia Inc., a biotechnology company that later merged with Sicor Inc. to become Gensia Sicor (and was later acquired by Teva Pharmaceuticals). He has also been a member of the Board of Directors of the Biotechnology Industry Organization and represented the biotechnology industry on the NASDAQ Corporate Advisory Board. Mr. Mendell is also a former Inc. magazine Entrepreneur of the Year. He has a bachelor's degree from UC Santa Barbara and a graduate degree in international management from The Thunderbird School of International Management.

Since 1999, Mr. Malchow, 55, has been President and Chief Executive Officer of Aliso Viejo, CA-based SenoRx (Nasdaq: SENO), which develops, manufactures and markets minimally invasive devices for the diagnosis and treatment of breast cancer. From 1993 to 1999, Mr. Malchow held various positions, including Chief Operating Officer, President and Chief Executive Officer, at Foster City, CA-based Penederm, a publicly traded drug delivery company acquired by Pittsburgh, PA-based Mylan Laboratories in 1998.

Mr. Malchow has also held executive positions at Allergan and American Hospital Supply. At Allergan he held several positions including Corporate Operating Committee Member, Vice President of Sales, Ophthalmology Vice President and General Manager of Skin Care. He currently serves on the Board of Directors of San Clemente, CA-based Rox Medical, a privately-held medical device company that develops products for the treatment of respiratory disease.

Mr. Malchow has a bachelor's degree from Carroll College, a master's degree from the University of Maryland and an MBA from Pepperdine University.

About Digirad Corporation

Digirad is a leading provider of diagnostic imaging products, and personnel and equipment leasing services. For more information, please visit www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding the efficacy of Digirad's centers of influence model, the status of the negotiation of the sale or closure of underperforming hub locations, and the ability to achieve positive cash flow and profitability, drive technology progress and improve services utilization to grow market share. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers' business conditions, work force, suppliers, business prospects, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

    Investor Contact:          Company Contact:
    -----------------          ----------------
    Matt Clawson               Todd Clyde, CEO
    Allen & Caron              858-726-1600
    949-474-4300               ir@digirad.com
    matt@allencaron.com


'/>"/>
SOURCE Digirad Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Digirad Corporation Reports First Quarter 2009 Financial Results
2. Digirad Corporation to Release First Quarter Financial Results on April 30, 2009
3. Digirad Receives 510(k) for Cardius X-ACT Rapid Cardiac SPECT/VCT Imager
4. Digirad Corporation Sells Arizona, Nevada Service Hubs
5. Digirad Names Richard B. Slansky Chief Financial Officer
6. Digirad Corporation Sells Northern California Service Hubs
7. Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009
8. Digirad Corporation Comments on Fourth Quarter Progress
9. Digirad Corporation CEO to Present at J.P. Morgan Healthcare Conference in San Francisco
10. Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation
11. Digirad Corporation Reports Financial Results for 2008 Second Quarter and Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... -- HealthMine surveys with 9,250 insured consumers fielded from February ... want help from their plans in five key areas: ... 2) help closing gaps in care, 3) better digital ... relevant, real-time guidance. Meeting these needs is essential to ... A Reason to Stay Engaged in Health ...
(Date:3/24/2017)... and GENEVA , March 24, ... World Tuberculosis Day revitalizes efforts to develop sutezolid as ... On World Tuberculosis Day, TB Alliance and the Medicines ... clinical development of sutezolid, an antibiotic drug candidate which ... to the development of sutezolid in combination with other ...
Breaking Medicine Technology: